Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100
Quince Therapeutics, Inc. QNCX | 0.00 |
- Quince Therapeutics held its annual shareholder meeting on June 11, 2026.
- Shareholders backed an amendment to authorize a reverse stock split, allowing a 1-for-10 to 1-for-100 ratio at the board’s discretion.
- The reverse split was authorized, not executed; timing and final ratio remain subject to a separate board decision.
- BDO USA was ratified as independent registered accounting firm for the fiscal year ending Dec. 31, 2026.
- Shareholders also authorized an adjournment if needed to continue soliciting proxies for the meeting’s proposals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-267862), on June 11, 2026, and is solely responsible for the information contained therein.
